370 results on '"De Stanchina, E"'
Search Results
2. MA19.03 SMARCA4 Controls State Plasticity in SCLC Through Regulation of Neuroendocrine Transcription Factors and REST Splicing.
3. Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
4. MA13.05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
5. MA05.04 Targeting TROP-2 In Diffuse Pleural Mesothelioma
6. Patient-Derived Tumor Xenograft
7. List of Contributors
8. Acquisition and Storage of Clinical Samples to Establish PDX Models
9. Methodologies for Developing and Maintaining Patient-Derived Xenograft Mouse Models
10. Running a PDX Core Laboratory or a PDX Support Program
11. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
12. 125P LSD1 inhibition restores MHC class I expression and augments the anti-tumor response of immune checkpoint blockade in small cell lung cancer
13. MA11.06 Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation
14. 2MO XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer
15. 1MO Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation
16. MA16.03 CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer
17. 1800O Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
18. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
19. 2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
20. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
21. p53 tumor suppressor protein regulates the levels of huntingtin gene expression
22. The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
23. 78 (PB068) - Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
24. P1.12-15 PET Imaging of [18F]PARP Inhibitor as a Pharmacodynamic Biomarker of Talazoparib in Small Cell Lung Cancer PDXs
25. MA21.01 Generation and Characterization of Novel Preclinical Disease Models of NSCLC with NRG1 Rearrangements to Improve Therapy
26. Blocking metastatic behavior of MUC16/CA-125-expressing cancer by targeting galectin-3
27. Chapter 1 - Patient-Derived Tumor Xenograft: Present and Future Challenges and Applications
28. Chapter 6 - Running a PDX Core Laboratory or a PDX Support Program
29. Chapter 3 - Methodologies for Developing and Maintaining Patient-Derived Xenograft Mouse Models
30. Chapter 2 - Acquisition and Storage of Clinical Samples to Establish PDX Models
31. PARP trapping by Talazoparib is a Potent Mechanism of Radiosensitization in Small Cell Lung Cancer Cell Lines and Patient-Derived Xenografts
32. MA22.01 PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency
33. Patient-derived xenograft models of prostate tumors
34. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
35. P3.15-008 [F18]PARPi PET as an In Vivo Pharmacodynamic Biomarker of PARP Inhibitor Therapy in Patient-Derived Xenografts of Small Cell Lung Cancer
36. [ 18 F]PARPi PET as a Marker of Intratumoral Talazoparib Level in Small Cell Lung Cancer
37. Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors
38. Abstract P4-14-24: Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling
39. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
40. [18F]PARPi PET as a Marker of Intratumoral Talazoparib Level in Small Cell Lung Cancer
41. Abstract PD1-8: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein
42. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
43. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
44. PML is induced by oncogenic ras and promotes premature senescence
45. Infrastructure Needs for Translational Integration of Mouse and Human Trials
46. Obstruction of BRAFV600Etranscription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth
47. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
48. Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors.
49. Transformation of rice by PEG-mediated plasmid uptake into protoplasts and rigeneration of transgenic plants
50. RNA fingerprinting with arbitrary-primed PCR and other applications of PCR for the search of plant molecular markers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.